Loading
Otolaryngology and Infectious Diseases · Journal article
Journal of Periodontal Research · August 14, 2026
Raises a question worth testing. It does not answer one.
This narrative review synthesizes evidence suggesting F. nucleatum plays context-dependent and often contradictory roles in cancer biology, with both pro-tumoural and anti-tumoural mechanisms coexisting within single cancer types. The authors argue against regarding F. nucleatum as universally pathogenic, and propose that its clinical impact is shaped by tumour microenvironment composition and interactions. The evidence remains fragmented across mechanistic and observational studies with no unified quantitative synthesis.
Narrative review. Patients with colorectal cancer and head and neck cancer; broader oncology populations implicated in mechanistic studies..
In colorectal cancer, F. nucleatum is predominantly associated with poorer outcomes through immune evasion and oncogenic signalling, yet also displays oncosuppressive activity via neutrophil-mediated and butyrate-driven mechanisms. In head and neck cancer, F. nucleatum detection is associated with improved survival across independent cohorts, suggesting a different balance of competing pro- and anti-tumoural mechanisms. Opposing pro- and anti-tumoural mechanisms can coexist within the same cancer type.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should not treat F. nucleatum detection as a uniform prognostic or therapeutic target; cancer type and microenvironmental context likely determine its clinical significance. Current evidence does not support F. nucleatum as a reliable biomarker or a target for cancer therapy without further mechanistic and clinical clarification.
A narrative review synthesizing existing evidence on mechanistic interactions between F. nucleatum and cancer, proposing context-dependent roles rather than reporting new primary data or a systematic synthesis with effect estimates.
As stated by the source record.
Clinicians should not treat F. nucleatum detection as a uniform prognostic or therapeutic target; cancer type and microenvironmental context likely determine its clinical significance. Current evidence does not support F. nucleatum as a reliable biomarker or a target for cancer therapy without further mechanistic and clinical clarification.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Fusobacterium is a genus of anaerobic Gram-negative bacteria that has been increasingly implicated in a range of diseases, including periodontitis and cancer. This review critically evaluates the reported role of Fusobacterium nucleatum in cancer, highlighting new findings that suggest a more nuanced cross-talk with the disease. We contextualise current evidence on the interactions with the wider tumour micro-environment, including the roles of polymicrobial communities, microbial metabolites and taxonomic heterogeneity. Collectively, the evidence suggests that Fusobacterium nucleatum should not be regarded as universally pathogenic or oncogenic. Rather, its behaviour is likely context-dependent and shaped by its surrounding microenvironment. Notably, opposing pro- and anti-tumoural mechanisms can coexist within the same cancer type. For example, in colorectal cancer, F. nucleatum is predominantly associated with poorer outcomes by promoting immune evasion (e.g., suppression of cytotoxic T cell responses) and oncogenic signalling (e.g., via the E-cadherin/β-catenin pathway), yet it also displays oncosuppressive activity through promotion of neutrophil-mediated anti-tumoural cytotoxicity and butyrate-driven cytotoxic T cell activation and potentiation of immunotherapy. In head and neck cancer, by contrast, F. nucleatum detection is associated with improved survival across independent cohorts, potentially reflecting a different balance of these same competing mechanisms. We suggest implications for its proposed use as a biomarker and as a target in cancer therapy. Lingering questions are also laid out to help investigators shape future research to better capture the complexity of the TME and elucidate the overall impact of Fusobacterium nucleatum in cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.